Food and Drug Administration
December 9, 2019
Bridget Kelley, Founder
Kelley Pure Essentials Oils
404 W. 5th St.
New Richmond, WI 54017
RE: Bergamot bergaptene free (Citrus bergamia), Listea Cubea, Cypress – Cupressus sempervirens, Cinnamon Leaf – Cinnamomum zeylanicum, Chamomile Roman – Anthemis nobilis, and Carrot Seed – Daucus carota
Dear Ms. Kelley:
This is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at www.kelleypureessentialoils.com in November 2019 and has found that you take orders there for various essential oil products including, but not limited to, Bergamot bergaptene free (Citrus bergamia), Listea Cubea, Cypress – Cupressus sempervirens, Cinnamon Leaf – Cinnamomum zeylanicum, Chamomile Roman – Anthemis nobilis, and Carrot Seed – Daucus carota. Various claims and statements made on your website establish that these products are drugs as defined in 21 U.S.C. § 321(g)(1) because they are intended for the treatment, cure, mitigation, or prevention of disease. For example, your website recommends or suggests the use of these products to prevent, treat, or cure depression, influenza, irritable bowel syndrome, hypertension, rheumatism, asthma, epilepsy, hepatitis, and hypercholesterolemia. As explained further below, the introduction of these product into interstate commerce for such uses violates the Federal Food, Drug, and Cosmetic Act.
These products are also new drugs as defined under 21 U.S.C. § 321(p) because they are not generally recognized as safe and effective for the uses recommended or suggested in their labeling. Before a new drug may be marketed or otherwise introduced into interstate commerce, it must be approved by FDA on the basis of scientific data demonstrating that the drug is safe and effective under the conditions of use in its labeling. See 21 U.S.C. §§ 355(a) and 331(d). Your drug products do not have FDA-approved applications as required by 21 U.S.C. § 355.
We advise you to review all materials through which you communicate to consumers the intended uses of your products, and to either submit a new drug application (NDA) for products intended for use in treating, curing, mitigating, diagnosing, or preventing a disease or, alternatively, remove all statements indicating that your products are intended for such uses. This would include reviewing your websites, product labels, catalogs, brochures, flyers, package inserts, audio and video, e-commerce and social media accounts you operate (e.g., Amazon, eBay, Facebook and Twitter accounts), as well as any other promotional materials, and removing product claims, consumer testimonials, metatags, and anything else that states or implies that your products are useful in treating, curing, mitigating, diagnosing, or preventing diseases.
Within 30 calendar days of the date of this letter, please correct the violations described in this letter and notify FDA, via electronic mail at FDAadvisory@fda.hhs.gov, that the violations have been corrected. Include the Online Advisory Letter Reference number (located in the upper right portion of this letter) in all your communications to FDA regarding this matter.
After 30 days from the date of this letter, if your websites or other labeling continue to demonstrate that your products are intended to treat, cure, mitigate, or prevent diseases, the name of your firm and this letter will be posted on the FDA webpage for products illegally marketed for serious diseases.
This letter is not intended to be an all-inclusive review of your websites or a list of all violations of law that exist in connection with your products, your websites and other product labeling, or at your facilities. FDA expects you to take the necessary steps to ensure that all your products comply with the laws and regulations enforced by FDA.
U.S. Food and Drug Administration